During the past decade, Baptist Health Research Institute conducted 15 clinical trials. In the 10-year time frame, 15 clinical trials started and 2 clinical trials were completed, i.e. on average, 13.3% percent of trials that started reached the finish line to date. In the past 5 years, 12 clinical trials started and 2 clinical trials were completed. i.e. 16.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Baptist Health Research Institute" #1 sponsor was "Rapid Medical" with 2 trials, followed by "Abiomed Inc." with 1 trials sponsored, "Biosense Webster, Inc." with 1 trials sponsored, "Boston Scientific Corporation" with 1 trials sponsored and "Duke University" with 1 trials sponsored. Other sponsors include 4 different institutions and companies that sponsored additional 14 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Baptist Health Research Institute" #1 collaborator was "Boehringer Ingelheim" with 1 trials as a collaborator, "Eli Lilly and Company" with 1 trials as a collaborator and "University of Calgary" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "Baptist Health Research Institute" are "Acute Ischemic Stroke" (3 trials), "Acute Myocardial Infarction" (1 trials), "Acute Respiratory Distress Syndrome" (1 trials), "Atrial Fibrillation" (1 trials) and "COVID 19" (1 trials). Many other conditions were trialed in "Baptist Health Research Institute" in a lesser frequency.

Most popular intervention types in "Baptist Health Research Institute" are "Device" (7 trials), "Drug" (4 trials), "Other" (3 trials), "Biological" (2 trials) and "Combination Product" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "CRT-D" (1 trials), "Comaneci Embolization Assist Device" (1 trials), "Efprezimod alfa" (1 trials) and "Impella CP® placement prior to reperfusion with Primary PCI" (1 trials). Other intervention names were less common.

The vast majority of trials in "Baptist Health Research Institute" are 15 trials for "All" genders.

Currently, there are NaN active trials in "Baptist Health Research Institute". undefined are not yet recruiting, 4 are recruiting, 4 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 5 completed trials in Baptist Health Research Institute, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Baptist Health Research Institute, 1 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 6 trials that are defined as “Not Applicable".